venBio Partners LLC

SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$495.9M2026 Q3
Positions9
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

venBio Partners LLC reported 9 positions worth $495.9M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: PBLS (34.3%). Biggest move: new buy ATTO ($71.7M).

9 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PBLSParabilis Medicines$170.1M34.29%5,266,697——-13.8%
▸ 2 PHVSPharvaris N.V.$141.4M28.52%4,458,977——+2.3%
▸ 3 ATTOAttovia Therapeutics$71.7M14.45%4,181,366——-11.7%
▸ 4 ACHVAchieve Life Sciences$47.9M9.65%5,914,720——-21.9%
▸ 5 ALMSAlumis$31.0M6.25%4,191,408——-30.4%
▸ 6 ALXOAlx Oncology$17.9M3.61%12,884,638——-25.2%
▸ 7 YARWYarrow Bioscience$12.5M2.52%554,769——-10.7%
▸ 8 LYELLyell Immunopharma$3.3M0.67%337,697——+49.6%
▸ 9 LSTALisata Therapeutics$225.3K0.05%156,460———

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does venBio Partners LLC hold as of Q3 2026?

venBio Partners LLC reported 9 positions worth $495.9M in its Q3 2026 13F filing. Largest positions: PBLS (34.3%), PHVS (28.5%), ATTO (14.5%), ACHV (9.6%) and ALMS (6.2%).

What did venBio Partners LLC buy in Q3 2026?

New positions: ATTO, YARW and LSTA.

What did venBio Partners LLC sell in Q3 2026?

Reduced: PHVS and ALMS. Sold out entirely: HRMY.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.